Xu Leyuan, Bai Qianming, Zhang Xin, Yang Hu
Department of Chemical and Life Science Engineering, Virginia Commonwealth University, Richmond, VA 23284, United States; Department of Internal Medicine, Yale University, New Haven, CT 06520, United States.
Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai 200032, China; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China.
J Control Release. 2017 Apr 28;252:73-82. doi: 10.1016/j.jconrel.2017.02.023. Epub 2017 Feb 22.
Folate receptor (FR) is highly expressed in many types of human cancers, and it has been actively studied for developing targeted chemotherapy and diagnostic agents. Tremendous efforts have been made in developing FR-targeted nanomedicines and nanoprobes and translating them into clinical applications. This article provides a concise review on the latest development of folate-mediated nanomedicines and nanoprobes for chemotherapy and diagnostics with an emphasis on in vivo applications. The cellular uptake mechanisms, pharmacokinetics (PK), administration routes and major challenges in FR-targeted nanoparticles are discussed.
J Control Release. 2017-4-28
J Control Release. 2016-6-16
J Pharm Sci. 2005-10
Chem Commun (Camb). 2012-7-6
Bioconjug Chem. 2012-6-26
Anticancer Agents Med Chem. 2016
Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2025
Nanomedicine (Lond). 2025-2
Drug Deliv Transl Res. 2025-1-3
MedComm (2020). 2024-10-15
Front Nutr. 2024-5-9
RSC Adv. 2023-7-17
Signal Transduct Target Ther. 2023-6-2
Drug Discov Today. 2016-7-14
J Control Release. 2016-3-28